Spots Global Cancer Trial Database for Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies
Official Title: Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies
Study ID: NCT01567722
Study Description
Brief Summary: RATIONALE: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies collecting tissue samples from patients with HIV-related malignancies.
Detailed Description: OBJECTIVES: * To obtain high-quality, clinically annotated tissue from patients with human immunodeficiency virus (HIV)-1 malignancy. * To study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the initiation and progression of HIV-1 malignancies, including complete genomic sequence determination of HIV-associated diffuse large B-cell lymphomas, lung cancer, anal cancer, and cervical cancer. OUTLINE: This is a multicenter study. Patients undergo tumor, lymph node, bone marrow, or skin biopsy, and peripheral blood mononuclear cells collection. Samples are submitted to the AIDS Malignancy Consortium (AMC) Biorepository and transferred to the AIDS and Cancer Specimen Resource (ACSR). Samples are then analyzed by the Genome Science Center of British Columbia (GSC-BC) and the HIV+ Tumor Molecular Characterization Project (HTMCP) for full genomic sequencing analysis that may include, but are not limited to, array-based gene expression profiling, comparative genome hybridization, and single nucleotide polymorphism studies by flow cytometry, cytogenetics, and molecular studies. Patients' clinical data, demographics, and treatment given are also collected prospectively in order to record treatment outcome and toxicity. Patients are followed up at 6 months, 1 year, and 2 years for data-reporting purposes.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moores UCSD Cancer Center, La Jolla, California, United States
UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
George Washington University, Washington, District of Columbia, United States
University of Miami, Miami, Florida, United States
John H. Stroger Hospital of Cook County, Chicago, Illinois, United States
Louisiana State University Public Hospital, New Orleans, Louisiana, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
University of Pennsylvania - Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Harborview Madison Clinic, Seattle, Washington, United States
Virginia Mason Medical Center, Seattle, Washington, United States
Contact Details
Name: Lee Ratner, MD, PhD
Affiliation: Washington University Siteman Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
